loading
Karyopharm Therapeutics Inc stock is traded at $0.624, with a volume of 484.86K. It is down -4.69% in the last 24 hours and down -18.59% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$0.657
Open:
$0.6649
24h Volume:
484.86K
Relative Volume:
0.54
Market Cap:
$82.91M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-0.4913
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
+0.66%
1M Performance:
-18.59%
6M Performance:
-22.81%
1Y Performance:
-58.94%
1-Day Range:
Value
$0.62
$0.6649
1-Week Range:
Value
$0.6015
$0.685
52-Week Range:
Value
$0.5809
$1.70

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
Name
Karyopharm Therapeutics Inc
Name
Phone
617-658-0600
Name
Address
85 WELLS AVENUE, NEWTON, MA
Name
Employee
325
Name
Twitter
@Karyopharm
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
0.624 82.91M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.20 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
716.19 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
652.89 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
275.00 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.92 28.75B 3.30B -501.07M 1.03B -2.1146

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-19-23 Initiated Piper Sandler Overweight
Nov-04-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-09-22 Upgrade JP Morgan Underweight → Neutral
Nov-19-21 Resumed Morgan Stanley Equal-Weight
Aug-06-21 Downgrade JP Morgan Overweight → Neutral
Aug-06-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-06-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-02-20 Initiated Morgan Stanley Overweight
Mar-04-20 Initiated Barclays Overweight
Jan-17-20 Downgrade Wedbush Outperform → Neutral
Jul-23-19 Upgrade JP Morgan Neutral → Overweight
Jul-05-19 Reiterated H.C. Wainwright Buy
Jul-05-19 Reiterated Robert W. Baird Outperform
Mar-01-19 Downgrade JP Morgan Overweight → Neutral
Feb-28-19 Reiterated BofA/Merrill Underperform
Feb-27-19 Downgrade BofA/Merrill Neutral → Underperform
Jan-03-19 Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18 Initiated B. Riley FBR Buy
Nov-09-18 Upgrade Wedbush Neutral → Outperform
May-24-18 Downgrade Wedbush Outperform → Neutral
Apr-02-18 Resumed Leerink Partners Outperform
Nov-15-17 Resumed H.C. Wainwright Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Sep-08-16 Reiterated H.C. Wainwright Buy
Aug-30-16 Upgrade Jefferies Hold → Buy
Aug-18-16 Initiated H.C. Wainwright Buy
Jun-28-16 Initiated Robert W. Baird Outperform
View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

pulisher
Feb 06, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Karyopharm awards stock options to top executives - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

A History of Outperforming Analyst Forecasts and Beating the Odds: Karyopharm Therapeutics Inc (KPTI) - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Karyopharm Therapeutics Inc: Rising -65.54% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

Karyopharm Therapeutics Inc [KPTI] President and CEO makes an insider sale of 4,055 shares worth $3175.0. - Knox Daily

Feb 05, 2025
pulisher
Feb 04, 2025

Karyopharm Therapeutics Inc (KPTI) stock analysis: A simple moving average approach - US Post News

Feb 04, 2025
pulisher
Feb 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Feb 03, 2025
pulisher
Feb 03, 2025

Daily Market Movement: Karyopharm Therapeutics Inc (KPTI) Sees a -6.32 Decrease, Closing at 0.62 - The Dwinnex

Feb 03, 2025
pulisher
Feb 02, 2025

Karyopharm awards stock options to top executives By Investing.com - Investing.com Australia

Feb 02, 2025
pulisher
Jan 31, 2025

Karyopharm Announces Executive Retention Equity Awards - TipRanks

Jan 31, 2025
pulisher
Jan 30, 2025

Karyopharm increases authorized shares, approves reverse split By Investing.com - Investing.com South Africa

Jan 30, 2025
pulisher
Jan 30, 2025

Karyopharm increases authorized shares, approves reverse split - Investing.com

Jan 30, 2025
pulisher
Jan 28, 2025

Karyopharm Therapeutics' SWOT analysis: biotech stock faces pivotal year By Investing.com - Investing.com Australia

Jan 28, 2025
pulisher
Jan 27, 2025

Karyopharm Therapeutics' SWOT analysis: biotech stock faces pivotal year - MSN

Jan 27, 2025
pulisher
Jan 25, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Barclays PLC Has $79,000 Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Barclays PLC Has $79,000 Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving AverageHere's Why - MarketBeat

Jan 25, 2025
pulisher
Jan 18, 2025

What is HC Wainwright’s Estimate for KPTI FY2024 Earnings? - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

What is HC Wainwright's Forecast for KPTI FY2024 Earnings? - MarketBeat

Jan 17, 2025
pulisher
Jan 15, 2025

HC Wainwright Reiterates Buy Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

Jane Street Group LLC Sells 1,345,226 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Jane Street Group LLC Has $170,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

Karyopharm announces preliminary 2024 revenue - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Karyopharm Reports $145M Revenue for 2024, Advances Phase 3 Myelofibrosis Trial - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives - PR Newswire

Jan 13, 2025
pulisher
Jan 10, 2025

Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media? - MSN

Jan 10, 2025
pulisher
Jan 10, 2025

Geode Capital Management LLC Has $1.13 Million Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

Jan 10, 2025
pulisher
Jan 10, 2025

Barclays PLC Sells 777,507 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat

Jan 10, 2025
pulisher
Jan 08, 2025

Karyopharm CEO sells common stock for $3,175 By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 06, 2025

12 Best Penny Stocks to Invest in According to the Media - Insider Monkey

Jan 06, 2025
pulisher
Jan 04, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Position Reduced by State Street Corp - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

Karyopharm appoints new CFO effective January 3 By Investing.com - Investing.com Australia

Jan 03, 2025
pulisher
Jan 02, 2025

Karyopharm appoints new CFO effective January 3 - Investing.com India

Jan 02, 2025
pulisher
Jan 02, 2025

Karyopharm Appoints Lori Macomber as Chief Financial Officer - citybiz

Jan 02, 2025
pulisher
Jan 02, 2025

Karyopharm Welcomes New Chief Financial Officer - Contract Pharma

Jan 02, 2025
pulisher
Jan 02, 2025

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025 - Marketscreener.com

Jan 02, 2025
pulisher
Jan 02, 2025

Karyopharm appoints new CFO to bolster financial strategy - Investing.com

Jan 02, 2025
pulisher
Jan 02, 2025

Karyopharm Therapeutics names Lori Macomber as CFO - MSN

Jan 02, 2025
pulisher
Jan 02, 2025

Karyopharm Appoints Lori Macomber as New CFO - TipRanks

Jan 02, 2025

Karyopharm Therapeutics Inc Stock (KPTI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Paulson Richard A.
President and CEO
Jan 06 '25
Sale
0.78
4,055
3,175
1,124,257
Paulson Richard A.
President and CEO
Dec 04 '24
Sale
0.81
3,620
2,932
1,128,312
Paulson Richard A.
President and CEO
Nov 05 '24
Sale
0.91
3,675
3,346
1,131,932
Paulson Richard A.
President and CEO
Oct 04 '24
Sale
0.88
3,607
3,172
1,135,607
Mano Michael
SVP, General Counsel&Secretary
Sep 04 '24
Sale
0.72
3,971
2,866
273,881
Paulson Richard A.
President and CEO
Sep 04 '24
Sale
0.72
3,667
2,647
1,139,214
Mason Michael
EVP, CFO & Treasurer
Sep 04 '24
Sale
0.72
7,050
5,089
391,054
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Sep 04 '24
Sale
0.72
5,356
3,866
404,051
Paulson Richard A.
President and CEO
Aug 06 '24
Sale
0.93
3,608
3,355
1,142,881
Poulton Stuart
EVP, Chief Development Officer
Jul 30 '24
Sale
1.06
2,883
3,056
326,628
$80.18
price down icon 0.61%
$20.10
price down icon 3.10%
$348.41
price down icon 1.47%
$4.73
price down icon 1.19%
biotechnology ONC
$222.79
price down icon 2.65%
$118.75
price down icon 0.97%
Cap:     |  Volume (24h):